Litcius/Paper detail

TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation

Jessica Ho, Bobo Wing-Yee Mok, Laura Campisi, Tristan X. Jordan, Soner Yildiz, Sreeja Parameswaran, Joseph A. Wayman, Natasha N. Gaudreault, David A. Meekins, Sabarish V. Indran, Igor Morozov, Jessie D. Trujillo, Yesai Fstkchyan, Raveen Rathnasinghe, Zeyu Zhu, Simin Zheng, Nan Zhao, Kris M. White, Helen Ray-Jones, Valeriya Malysheva, Michiel J. Thiecke, S. Lau, Honglian Liu, Anna Junxia Zhang, Andrew Chak-Yiu Lee, Wen‐Chun Liu, Sonia Jangra, Alba Escalera, Teresa Aydillo, Betsaida Salom Melo, Ernesto Guccione, Robert Sebra, Elaine Shum, Jan Bakker, David A. Kaufman, André L. Moreira, Mariano Carossino, Udeni B. R. Balasuriya, Minji Byun, Randy A. Albrecht, Michael Schotsaert, Adolfo García‐Sastre, Sumit K. Chanda, Emily R. Miraldi, Anand D. Jeyasekharan, Benjamin R. tenOever, Mikhail Spivakov, Matthew T. Weirauch, Sven Heinz, Honglin Chen, Christopher Benner, Jüergen A. Richt, Ivan Marazzi

2021Cell123 citationsDOIOpen Access PDF

Topics & Concepts

BiologyInflammationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSars virusImmunologyDiseaseInfectious disease (medical specialty)Internal medicineOutbreakMedicineinterferon and immune responsesSARS-CoV-2 and COVID-19 ResearchPhagocytosis and Immune Regulation
TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation | Litcius